Cargando…

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations

The development of resistance to previously effective treatments has been a challenge for health care providers and a fear for patients undergoing cancer therapy. This is an unfortunately frequent occurrence for patients undergoing targeted therapy for tumours harboring the activating V600E mutation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Obaid, Nourah Mohammad, Bedard, Karen, Huang, Weei-Yuarn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372601/ https://www.ncbi.nlm.nih.gov/pubmed/28282860 http://dx.doi.org/10.3390/ijms18030585

Ejemplares similares

Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours
por: Paton, Emily L., et al.
Publicado: (2020)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation
por: Caliò, Anna, et al.
Publicado: (2016)

Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance
por: Kim, Namkyoung, et al.
Publicado: (2021)

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
por: Chan, Xian Yang, et al.
Publicado: (2017)

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
por: Le Calvez, Baptiste, et al.
Publicado: (2020)

Deep learning for computer-assisted diagnosis of hereditary diffuse gastric cancer
por: Rasmussen, Sean A., et al.
Publicado: (2021)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS
por: Fleischmann, Maximilian, et al.
Publicado: (2023)

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
por: Novak, Jennifer, et al.
Publicado: (2022)

Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease
por: Cronin, Christopher, et al.
Publicado: (2022)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

In search of effective therapies to overcome resistance to Temozolomide in brain tumours
por: Bouzinab, Kaouthar, et al.
Publicado: (2019)

BRAF Mutation in Hairy Cell Leukemia
por: Ahmadzadeh, Ahmad, et al.
Publicado: (2014)

Innovative Strategies to Overcome Biofilm Resistance
por: Taraszkiewicz, Aleksandra, et al.
Publicado: (2013)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors
por: Mulcahy Levy, Jean M, et al.
Publicado: (2017)

Innovative Strategies to Overcome Antimicrobial Resistance and Tolerance
por: Choudhary, M. Iqbal, et al.
Publicado: (2022)

Papillary thyroid cancer organoids harboring BRAF(V600E) mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
por: Chen, Dong, et al.
Publicado: (2023)

BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies
por: Wang, Pei-Pei, et al.
Publicado: (2022)

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report
por: Shen, Qian, et al.
Publicado: (2021)

Claudin-1 Expression Is Elevated in Colorectal Cancer Precursor Lesions Harboring the BRAF V600E Mutation()()
por: Caruso, Maria, et al.
Publicado: (2014)

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
por: Čepulytė, Rūta, et al.
Publicado: (2020)

Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib
por: Kian, Waleed, et al.
Publicado: (2023)

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
por: JIAPAER, Shabierjiang, et al.
Publicado: (2018)

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib
por: Guo, Weihong, et al.
Publicado: (2022)

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
por: Spagnolo, Francesco, et al.
Publicado: (2015)

Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells
por: Fisher, Matthew L., et al.
Publicado: (2017)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
por: Azimi, Alireza, et al.
Publicado: (2018)

Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
por: Pópulo, Helena, et al.
Publicado: (2021)

Novel agents and strategies for overcoming EGFR TKIs resistance
por: Niu, Fei-Yu, et al.
Publicado: (2014)

Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
por: Hattinger, Claudia Maria, et al.
Publicado: (2023)

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
por: Soung, Young-Hwa, et al.
Publicado: (2023)

BRAF Mutation in Colorectal Cancer: An Update
por: Barras, David
Publicado: (2015)

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
por: Fernandes, Gustavo S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fvbablevi5jl980tmrppc6mn7g